

ASX ANNOUNCEMENT

7 May 2026

## Results of 2026 Annual Meeting of Stockholders

**Sunnyvale, California; 7 May 2026:** EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), refers to the Annual Meeting of Stockholders held today. The results of the meeting are set out in the attached document in accordance with ASX Listing Rule 3.13.2. All resolutions were decided and passed by way of poll.

ENDS

*This announcement has been authorised for release by the Routine Disclosure Committee, a Committee of the Board.*

**For more information, please contact:**

### Company

Andrew Shute  
Chief Corporate Development Officer  
P: +44 7730 691421  
E: [info@ebrwise.com](mailto:info@ebrwise.com)

### Investor Relations

Gabriella Hold  
The Capital Network  
P: +61 2 8999 3699  
E: [gaby@thecapitalnetwork.com.au](mailto:gaby@thecapitalnetwork.com.au)

### About EBR Systems

Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

### EBR Systems’ WiSE Technology

EBR Systems’ WiSE technology is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart’s left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart’s left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device in most markets and is currently only available for sale in the US.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company’s control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products and achieve broad market adoption including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory applications and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. These forward-looking statements are based on EBR Systems’ current

**EBR SYSTEMS, INC.** (ARBN 654 147 127)

480 Oakmead Parkway, Sunnyvale CA 94085 USA T: +1 408 720 1906 W: <https://ebrsystemsinc.com/>

expectations and inherently involve significant risks and uncertainties. EBR Systems' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of certain risks and uncertainties including those risks described in more detail in its most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents on file with the SEC from time to time and available on the SEC's website at [www.sec.gov](http://www.sec.gov).

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

#### **Foreign Ownership Restriction**

EBR's ASX-traded (ASX: EBR) CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

For personal use only

## Results of meeting

Name of entity

EBR Systems, Inc.

ARBN

654 147 127

Date of meeting

7 May 2026 AEST (6 May 2026 PDT)

Resolutions voted on at the meeting					If decided by poll <sup>5</sup>					Proxies received <sup>6</sup>			
Resolution		Result <sup>2</sup>	Voting method <sup>3</sup>	If s250U applies <sup>4</sup>	Voted for		Voted against		Abstained	For	Against	Abstain	Discretion <sup>9</sup>
No <sup>1</sup>	Short description				Number	% <sup>7</sup>	Number	% <sup>8</sup>					
1(a)	Re-election of Mr. John McCutcheon	Passed	Poll	N/A	219,279,816	99.03	2,140,682	0.97	-	219,279,816 (99.03%)	2,140,682 (0.97%)	-	-
1(b)	Re-election of Dr Bronwyn Evans	Passed	Poll	N/A	219,339,937	99.06	2,080,561	0.94	-	219,339,937 (99.06%)	2,080,561 (0.94%)	-	-
2	2021 Equity Incentive Plan	Passed	Poll	N/A	166,610,416	92.98	12,056,707	6.73	525,446	166,610,416 (92.98%)	12,056,707 (6.73%)	525,446	-
3	Grant of Options to Mr. John McCutcheon	Passed	Poll	N/A	175,654,250	98.02	3,273,635	1.83	264,684	175,654,250 (98.02%)	3,273,635 (1.83%)	264,684	-
4	Grant of Options to Mr. Allan Will	Passed	Poll	N/A	175,581,950	97.98	3,345,935	1.87	264,684	175,581,950 (97.98%)	3,345,935 (1.87%)	264,684	-
5	Grant of Options to Ms. Karen Drexler	Passed	Poll	N/A	175,639,625	98.01	3,288,260	1.84	264,684	175,639,625 (98.01%)	3,288,260 (1.84%)	264,684	-
6	Grant of Options to Mr. Trevor Moody	Passed	Poll	N/A	175,614,625	98.00	3,288,260	1.84	289,684	175,614,625 (98.00%)	3,288,260 (1.84%)	289,684	-
7	Grant of Options to Dr. David Steinhaus	Passed	Poll	N/A	175,614,625	98.00	3,288,260	1.84	289,684	175,614,625 (98.00%)	3,288,260 (1.84%)	289,684	-
8	Grant of Options to a holding nominated by Dr. Bronwyn Evans	Passed	Poll	N/A	175,615,725	98.01	3,287,160	1.83	289,684	175,615,725 (98.01%)	3,287,160 (1.83%)	289,684	-
9	Grant of Options to a nominated entity of Dr. Christopher Nave	Passed	Poll	N/A	175,614,625	98.01	3,284,210	1.83	293,734	175,614,625 (98.01%)	3,284,210 (1.83%)	293,734	-

<b>Resolutions proposed but not put to the meeting<sup>10</sup></b>		
<b>No<sup>1</sup></b>	<b>Short description</b>	<b>Reason(s) for not putting the resolution to the meeting</b>

personal use only